Iterum Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Iterum Therapeutics (NASDAQ:ITRM) is scheduled to release its quarterly earnings report on March 28, 2024, with an estimated EPS of $-0.93. Historical data shows mixed reactions to past earnings, with the last quarter missing estimates but resulting in a 10.76% share price increase. Shares are currently at $1.56, up 57.25% over the last year. Investors are advised to watch for earnings performance and guidance for future growth.
March 27, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Iterum Therapeutics is expected to report an EPS of $-0.93 for the latest quarter. Historical performance shows variable stock price reactions to earnings reports. Shares have risen 57.25% over the past year, indicating positive investor sentiment.
The expected EPS and historical earnings performance suggest a cautious outlook. The stock's positive year-over-year performance indicates strong investor sentiment, but the actual impact of the earnings report will depend on whether Iterum Therapeutics meets or exceeds expectations and provides positive future guidance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100